Cargando…

Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old

CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros, Giuliana X., Sasahara, Greyce Luri, Magawa, Jhosiene Y., Nunes, João Paulo S., Bruno, Fernanda R., Kuramoto, Andreia C., Almeida, Rafael R., Ferreira, Marcelo A., Scagion, Guilherme P., Candido, Érika D., Leal, Fabyano B., Oliveira, Danielle B. L., Durigon, Edison L., Silva, Roberto Carlos V., Rosa, Daniela S., Boscardin, Silvia B., Coelho, Verônica, Kalil, Jorge, Santos, Keity S., Cunha-Neto, Edecio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921991/
https://www.ncbi.nlm.nih.gov/pubmed/35300337
http://dx.doi.org/10.3389/fimmu.2022.812126
_version_ 1784669433923371008
author Medeiros, Giuliana X.
Sasahara, Greyce Luri
Magawa, Jhosiene Y.
Nunes, João Paulo S.
Bruno, Fernanda R.
Kuramoto, Andreia C.
Almeida, Rafael R.
Ferreira, Marcelo A.
Scagion, Guilherme P.
Candido, Érika D.
Leal, Fabyano B.
Oliveira, Danielle B. L.
Durigon, Edison L.
Silva, Roberto Carlos V.
Rosa, Daniela S.
Boscardin, Silvia B.
Coelho, Verônica
Kalil, Jorge
Santos, Keity S.
Cunha-Neto, Edecio
author_facet Medeiros, Giuliana X.
Sasahara, Greyce Luri
Magawa, Jhosiene Y.
Nunes, João Paulo S.
Bruno, Fernanda R.
Kuramoto, Andreia C.
Almeida, Rafael R.
Ferreira, Marcelo A.
Scagion, Guilherme P.
Candido, Érika D.
Leal, Fabyano B.
Oliveira, Danielle B. L.
Durigon, Edison L.
Silva, Roberto Carlos V.
Rosa, Daniela S.
Boscardin, Silvia B.
Coelho, Verônica
Kalil, Jorge
Santos, Keity S.
Cunha-Neto, Edecio
author_sort Medeiros, Giuliana X.
collection PubMed
description CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection.
format Online
Article
Text
id pubmed-8921991
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89219912022-03-16 Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old Medeiros, Giuliana X. Sasahara, Greyce Luri Magawa, Jhosiene Y. Nunes, João Paulo S. Bruno, Fernanda R. Kuramoto, Andreia C. Almeida, Rafael R. Ferreira, Marcelo A. Scagion, Guilherme P. Candido, Érika D. Leal, Fabyano B. Oliveira, Danielle B. L. Durigon, Edison L. Silva, Roberto Carlos V. Rosa, Daniela S. Boscardin, Silvia B. Coelho, Verônica Kalil, Jorge Santos, Keity S. Cunha-Neto, Edecio Front Immunol Immunology CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8921991/ /pubmed/35300337 http://dx.doi.org/10.3389/fimmu.2022.812126 Text en Copyright © 2022 Medeiros, Sasahara, Magawa, Nunes, Bruno, Kuramoto, Almeida, Ferreira, Scagion, Candido, Leal, Oliveira, Durigon, Silva, Rosa, Boscardin, Coelho, Kalil, Santos and Cunha-Neto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Medeiros, Giuliana X.
Sasahara, Greyce Luri
Magawa, Jhosiene Y.
Nunes, João Paulo S.
Bruno, Fernanda R.
Kuramoto, Andreia C.
Almeida, Rafael R.
Ferreira, Marcelo A.
Scagion, Guilherme P.
Candido, Érika D.
Leal, Fabyano B.
Oliveira, Danielle B. L.
Durigon, Edison L.
Silva, Roberto Carlos V.
Rosa, Daniela S.
Boscardin, Silvia B.
Coelho, Verônica
Kalil, Jorge
Santos, Keity S.
Cunha-Neto, Edecio
Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title_full Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title_fullStr Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title_full_unstemmed Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title_short Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
title_sort reduced t cell and antibody responses to inactivated coronavirus vaccine among individuals above 55 years old
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921991/
https://www.ncbi.nlm.nih.gov/pubmed/35300337
http://dx.doi.org/10.3389/fimmu.2022.812126
work_keys_str_mv AT medeirosgiulianax reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT sasaharagreyceluri reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT magawajhosieney reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT nunesjoaopaulos reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT brunofernandar reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT kuramotoandreiac reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT almeidarafaelr reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT ferreiramarceloa reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT scagionguilhermep reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT candidoerikad reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT lealfabyanob reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT oliveiradaniellebl reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT durigonedisonl reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT silvarobertocarlosv reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT rosadanielas reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT boscardinsilviab reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT coelhoveronica reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT kaliljorge reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT santoskeitys reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold
AT cunhanetoedecio reducedtcellandantibodyresponsestoinactivatedcoronavirusvaccineamongindividualsabove55yearsold